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Background—Mast cell chymase may participate in the pathogenesis of human abdominal aortic aneurysm (AAA), yet a
direct contribution of this serine protease to AAA formation remains unknown.
Methods and Results—Human AAA lesions had high numbers of chymase-immunoreactive mast cells. Serum chymase
level correlated with AAA growth rate (P0.009) in a prospective clinical study. In experimental AAA produced by
aortic elastase perfusion in wild-type (WT) mice or those deficient in the chymase ortholog mouse mast cell protease-4
(mMCP-4) or deficient in mMCP-5 (Mcpt4/, Mcpt5/), Mcpt4/ but not Mcpt5/ had reduced AAA formation 14
days after elastase perfusion. Even 8 weeks after perfusion, aortic expansion in Mcpt4/ mice fell by 50% compared
with that of the WT mice (P0.0003). AAA lesions in Mcpt4/ mice had fewer inflammatory cells and less apoptosis,
angiogenesis, and elastin fragmentation than those of WT mice. Although KitW-sh/W-sh mice had protection from AAA
formation, reconstitution with mast cells from WT mice, but not those from Mcpt4/ mice, partially restored the AAA
phenotype. Mechanistic studies suggested that mMCP-4 regulates expression and activation of cysteine protease
cathepsins, elastin degradation, angiogenesis, and vascular cell apoptosis.
Conclusions—High chymase-positive mast cell content in human AAA lesions, greatly reduced AAA formation in
Mcpt4/ mice, and significant correlation of serum chymase levels with human AAA expansion rate suggests
participation of mast cell chymase in the progression of human and mouse AAA. (Circulation. 2009;120:973-982.)
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Human chymases, which are mast cell-restricted serineproteases, can activate matrix metalloproteinases
(MMPs),1 produce angiotensin II,2 induce endothelial cell
(EC) and smooth muscle cell (SMC) apoptosis,3,4 and de-
grade constituents of high-density lipoprotein particles, thereby
impairing their cholesterol efflux ability.5 Therefore, mast cell
chymases may contribute to arterial remodeling in atheroscle-
rosis and abdominal aortic aneurysm (AAA) formation. AAA
involves extensive arterial extracellular matrix degradation,
aortic cell apoptosis, and microvessel accumulation.6 To date,
we lack a clinically useful soluble biomarker for AAA, and
invasive repair is the only treatment for this life-threatening
human disease.7 Although a direct link between chymase and
AAA remains conjectural, extracts from human aneurysmal
aortas have significantly higher mast cell chymase–associated
angiotensin II–forming activity than those from control aor-
tas,8 consistent with the observation of high numbers of
chymase-positive mast cells in the adventitia and media of
aneurysmal aortas.9 We recently established an important role
of mast cells in AAA in 2 mouse preparations.10 Although the
role of mast cell–derived chymases in the pathogenesis of
AAA remains untested, mast cell–deficient KitW-sh/W-sh mice
had greatly attenuated AAA formation after aortic elastase
perfusion and periaortic CaCl2 injury compared with wild-
type (WT) control mice. Inhibition of mast cell chymase
activities with a small-molecule inhibitor, NK3201, reduced
elastase perfusion–induced AAA formation in dogs, ham-
sters, and mice.11–13 Reduced AAA formation occurs with
lower MMP-9 activity and mast cell numbers in the aortas.
These data suggested that mast cell chymases contribute
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importantly to AAA formation, although detailed mecha-
nisms remain unclear, and this inhibitor could have pertinent
nonspecific effects.
Clinical Perspective on p 982
Protease-deficient animals permit direct testing of the
functions of individual enzymes in pathological processes,
including AAA.14,15 Unlike human chymase, the product of a
solitary gene belonging to the -chymase family, mice have
a chymase family consisting of mouse mast cell proteases
(mMCP)-1, -2, -4, -5, and -9. The -chymases mMCP-1 and -2
are expressed mainly in mucosal mast cells, whereas the
-chymase mMCP-9 is expressed mainly in the uterus. In
contrast, the connective tissue mast cells in most sites express the
-chymase mMCP-4 and the -chymase mMCP-5. mMCP-4
appears to be the predominant mast cell chymase within mouse
connective tissues.16 Therefore, mMCP-4 may be the most
relevant human chymase ortholog in arterial remodeling. This
study used mMCP-4–deficient (Mcpt4/) and mMCP-5–defi-
cient (Mcpt5/) mice to test the hypothesis that these connective
tissue chymases impair AAA formation directly in mice with
AAA induced by aortic elastase perfusion.
Methods
Human AAA Lesion Sections and Serum Samples
Paraffin-embedded human aortic sections were prepared from 10 AAA
donors (5 females and 5 males; mean age, 78.802.05 years) and 10
non-AAA heart transplant patients (5 females and 5 males; mean age,
41.904.19 years) without detectable vascular diseases from the De-
partment of Surgery, Washington University, St Louis, Mo. These
sections helped to detect chymase expression with the use of mouse
anti-human chymase monoclonal antibody (Abcam). Human aortic
tissue extracts were prepared from 3 female AAA patients and 3 female
heart transplant donors with no detectable vascular disease from the
Department of Medicine, Brigham and Women’s Hospital, Boston,
Mass. Tissue lysates were used for immunoblot analysis (30 g per
lane) with the same antibody. The same blot was reprobed for -actin to
affirm equal protein loading. Separate human protocols were preap-
proved by the Human Investigation Review Committees at Washington
University and at Brigham and Women’s Hospital.
To establish the correlation of AAA expansion rates to serum
chymase levels, we developed a human chymase enzyme-linked
immunosorbent assay system. Briefly, mouse anti-human chymase
antibody (AbD, Serotec) was used to coat a 96-well plate. Serum
samples were diluted (1:100) and incubated on a precoated plate for
2 hours at room temperature. Biotinylated mouse anti-human chy-
mase monoclonal antibody (Millipore) was used as detecting anti-
body. Detailed antibody information is listed in Table I in the
online-only Data Supplement.
Serum samples from 103 male AAA patients were identified by a
previously described population-based screening of 65- to 73-year-
old men at the Department of Vascular Surgery, Viborg Hospital,
Viborg, Denmark.17 A total of 4404 men were invited to participate
in this follow-up study. Of 3344 participants, 141 (4.2%) had AAA,
defined as an infrarenal aortic diameter of 30 mm. Of those with
AAA, 19 had diameters50 mm who were referred for surgery, and
10 were lost to follow-up. A total of 112 were followed for 1 year
(on average, for 2.9 years). Of 112 cases, 103 had serum chymase
measured blindly and data presented. All participants gave informed
consent. Detailed patient information was reported previously.17
Mouse AAA Model and Lesion Characterization
C57BL/6 WT mice were purchased from The Jackson Laboratory
(Bar Harbor, Me). Mcpt4/ and Mcpt5/ C57BL/6 mice have been
backcrossed to the same background for 10 and 4 generations,
respectively.18,19 Ten-week-old mice from each type were used for
aortic elastase perfusion–induced AAA.14 Aneurysmal lesions were
collected 7, 14, and 56 days after elastase perfusion. Mouse aortic
diameters were measured before and after elastase perfusion and at
the end of each time point. Aortic diameter expansion 100% of that
before perfusion defined AAA, according to Pyo et al.14 Each mouse
aorta was isolated for both frozen section preparation and tissue
protein extraction in a pH 5.5 buffer.17 Frozen sections were used for
immunostaining for macrophages (Mac-3), SMCs (-actin), T cells
(CD3), apoptotic cells (terminal deoxynucleotidyl transferase–medi-
ated dUTP nick-end labeling [TUNEL]), microvessels (CD31),
chemokine (monocyte chemotactic protein-1 [MCP-1]), mast cells
(c-Kit, CD117), and elastin degradation (Verhoeff–van Gieson)
(Table I in the online-only Data Supplement). SMC content and
elastin fragmentation were graded as described previously.17 T cells,
apoptotic cells, mast cells, MCP-1–positive cells, and microvessel
numbers were counted blindly. Macrophage-positive areas were
measured with the use of computer-assisted image analysis software
(Image-Pro Plus; Media Cybernetics, Bethesda, Md).
Bone Marrow–Derived Mast Cell Preparation and
KitW-sh/W-sh Reconstitution
Bone marrow–derived mast cells (BMMCs) were prepared and
verified as described previously.20 For KitW-sh/W-sh mice reconstitution,
recipient mice at 5 weeks of age were given 1107 of BMMCs from
WT or Mcpt4/ mice via the tail vein. Five weeks after BMMC
reconstitution, mice were introduced to the AAA model. Mouse
abdominal aortas were harvested 14 and 56 days after elastase
perfusion.
BMMC In Vitro Activity Assays
An aortic ring angiogenesis assay was performed by incubating
Matrigel-embedded WT mouse aortic rings in a 96-well plate with live
BMMCs from WT and Mcpt4/ mice (3105 cells per 150 L
RPMI-1640 with 10% fetal bovine serum per well) for 7 to 10 days. EC
growth areas were determined with the use of Image-Pro Plus software
and presented as square millimeters. Vascular endothelial growth factor
(VEGF) (10 ng/mL; PeproTech) was used as a positive control.
Real-time polymerase chain reaction (RT-PCR) was used to
determine protease mRNA levels in BMMCs. Total cellular RNA
was extracted from BMMCs with the use of TRIzol reagent
(GIBCO) and treated with RNase-free DNase (Ambion) to remove
genomic DNA contaminants. Equal amounts of RNA were reverse-
transcribed, and quantitative PCR was assessed in a single-color
RT-RCR detection system (Stratagene). The level of each protease
transcript was normalized to that of the -actin transcript.
BMMC and aortic tissue extract cysteinyl cathepsin activities were
examined with biotin-conjugated JPM, an affinity probe that labels
active cathepsins specifically and irreversibly.17 Briefly, BMMC and
pulverized aortic tissues were lysed into a pH 5.5 buffer. Five
micrograms of protein from each sample was incubated with
12 mmol/L dithiothreitol and 1 L of biotin-conjugated JPM in 30
L of a pH 5.5 buffer for 1 hour at 37°C. Protein samples were then
separated on a 12% SDS-PAGE followed by immunoblot detection
with horseradish peroxidase–conjugated avidin (Table I in the
online-only Data Supplement). BMMC lysate MMP activity was
detected with a gelatin gel zymogram, essentially the same as
reported previously.21
BMMC activity in promoting vascular SMC apoptosis was per-
formed with the use of primary cultured mouse aortic SMC on an
8-well chamber slide.10 Confluent SMCs were stimulated to apopto-
sis overnight with 80 mol/L pyrrolidinedithiocarbamate with and
without 300 L of degranulated BMMC supernatant in Dulbecco’s
modified Eagle’s medium (1106 BMMC supernatant/mL) from
WT or Mcpt4/ mice as described.22 Apoptotic cells were detected
with an In Situ Cell Death Detection Kit according to the instructions
(Roche Diagnostics Co).
BMMC elastase activities were determined by mixing 100 g of
BMMC extract with 20 g of fluorogenic elastin (DQ-elastin,
Molecular Probes, Carlsbad, Calif) in 100 L of a pH 5.5 buffer on
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a 96-well plate for 5 hours. The plate was read at excitation/
emission505/515 nm, and data were presented as relative fluores-
cence units.
Statistical Analysis
The annual growth rate of human AAA during the first year after
serum sampling was calculated as the difference between maximal
anterior-posterior AAA diameter divided by the observation time.
The crude correlation between serum chymase, AAA size, and
growth rate was calculated with Pearson correlation test. Multivari-
ate linear regression analysis was performed to adjust for the
subjects’ use of glucocorticoids, smoking, low-dose aspirin, angio-
tensin-converting enzyme inhibitor, -adrenergic blocker,
-adrenergic agonist, lowest ankle-brachial blood pressure index,
diastolic blood pressure, and age.
Because of small sample size and abnormal data distribution, a
Mann–Whitney U test was used for data from mouse experiments
throughout the study. P values 0.05 were considered statistically
significant.
Results
Increased Chymase Expression in Human
AAA Lesions
Human AAA lesions had many more chymase-
immunoreactive mast cells than did healthy aortas. Chymase-
positive mast cells localized throughout the AAA lesions
from media to adventitia (Figure 1A and 1B). In contrast, the
media and adventitia of human aortas without AAA had
many fewer chymase-positive mast cells (Figure 1C). Con-
sistent with this observation, immunoblot analysis of aortic
tissue extracts showed 11-fold higher levels of chymase
proteins by densitometry in AAA than in normal aortas after
the protein loading for -actin signals was normalized (Im-
ageJ) (Figure 1D).
Correlation of Serum Chymase Level With AAA
Growth Rate
In this serological prospective study of 103 AAA patients
who had serum chymase measured, Pearson correlation test
did not reveal significant associations between chymase and
initial AAA size (r0.02, P0.833). However, serum chy-
mase levels correlated modestly with AAA growth rate
(r0.19, P0.06). Because of the various medications used
by these patients, we performed a multivariate linear regres-
sion analysis by adjusting for potentially known confounders
of AAA, including smoking, low-dose aspirin, use of angio-
tensin-converting enzyme inhibitors, -adrenergic blocking
agents, -adrenergic agonists, or corticosteroids, ankle-
brachial index, diastolic blood pressure, and age. Among
these confounders, serum chymase and glucocorticoid use
correlated strongly and significantly with AAA growth rate
after the adjustment (P0.009) (Table). Although we do not
know the cause, glucocorticoid users had higher AAA growth
rate (3.540.49 versus 1.970.19 mm/y; P0.01) but lower
serum chymase levels (10.770.31 versus 12.340.24 ng/
mL; P0.04) than nonglucocorticoid users. Therefore, chy-
mase expression alone may not explain the glucocorticoid
effects on AAA growth. Other unrecognized mechanisms
may play more important roles. After those receiving glu-
cocorticoid treatments were excluded (n10), the modest
correlation between serum chymase and AAA growth rate
became significant (r0.26, P0.01), although we did not
see any correlation among the glucocorticoid users (r0.07,
P0.84) (Figure 1E).
Reduced AAA Formation in mMCP-4–Deficient Mice
Increased chymase-positive mast cells in human AAA lesions
and significant association of serum chymase levels with
AAA growth rate suggested the involvement of chymases in
AAA development. To test this hypothesis directly, we
performed elastase aortic perfusion to induce AAA in
Mcpt4/ and Mcpt5/ mice.14 Analysis at 7 and 14 days
after perfusion did not show significant differences in aortic
expansion between WT and Mcpt5/ mice (data not shown).
Figure 1. Chymase expression in human AAA lesions. A, Human AAA lesion chymase immunostaining demonstrated chymase-positive
mast cells in the media (Med). B, Human AAA lesion chymase immunostaining demonstrated chymase-positive mast cells in the adven-
titia (Adv). C, Many fewer chymase-positive mast cells were seen in media or adventitia from aortas of heart transplant donors who had
no detectable vascular diseases. Arrows indicate chymase-positive mast cells. Purified mouse IgG was used as immunostaining nega-
tive controls (not shown). D, Human aortic tissue chymase Western blot analysis. -Actin immunoblot was used for protein loading
control. E, Correlation of serum chymase and AAA growth rate among patients with (filled circles) or without (empty circles) glucocorti-
coid treatments (Pearson correlation test). P0.05 was considered statistically significant.
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In contrast, whereas all WT mice developed AAA 14 days
after elastase perfusion (100% incidence), none of the
Mcpt4/ mice did (0% incidence) (P0.0001). Analysis 56
days after perfusion still showed significant attenuation of
AAA expansion (P0.0003) and lower incidences (69%
versus 100%) in Mcpt4/ mice compared with WT mice
(Figure 2A). Inflammatory cell accumulation, including
Mac-3 macrophages (Figure 2B) and CD3 T cells (Figure
2C), also diminished in Mcpt4/ mice relative to WT control
mice at the 14-day or 56-day time point. In contrast, aortas
from Mcpt4/ mice had more SMCs than those from WT
mice 7 days after perfusion (Figure 2D), although such
differences diminished at later time points.
Apoptosis, angiogenesis, and elastin loss characterize hu-
man AAA.6 To examine whether reduced AAA in Mcpt4/
mice also impaired these variables, we performed TUNEL
(apoptosis), CD31 (angiogenesis), and Verhoeff–van Gieson
(elastin) staining with frozen aortic sections prepared from
WT and Mcpt4/ mice from different time points. As we
anticipated, the numbers of both apoptotic cells and CD31
microvessels as well as the degree of elastin fragmentation
fell significantly in AAA lesions from Mcpt4/ mice com-
pared with those from WT control mice at most of the time
points examined, although not at all time points (Figure 2E
through 2G), suggesting that multiple variables contributed to
reduced AAA in Mcpt4/ mice and that chymase expression
affected these variables differently at assorted time points.
Reduced AAA in Mcpt4/ mice did not result from altered
accumulation of mast cells in AAA lesions. Lesion MCP-1
or CD117 cell content did not differ between the 2 groups
(data not shown).
Mast Cell Reconstitution and AAA Formation in
Mast Cell–Deficient Mice
Reduced AAA in Mcpt4/ mice might not result solely from
the lack of mMCP-4 because aside from mast cells, mMCP-4
deficiency may affect other cell types, which could contribute
indirectly to AAA formation. To examine this hypothesis, we
reconstituted mast cell–deficient KitW-sh/W-sh mice with BM-
MCs from WT or Mcpt4/ mice. Consistent with our earlier
observation, KitW-sh/W-sh mice failed to develop AAA,10 and
provision of WT BMMCs restored AAA expansion at both
the 14- and 56-day time points. In contrast, those that
received BMMCs from Mcpt4/ mice remained protected
from aortic expansion at both time points (Figure 3A).
In addition to measuring aortic diameters for those
BMMC-reconstituted mice, we also determined their lesion
macrophage and T cell content, CD31 microvessel number,
total apoptotic cell number, and elastin fragmentation. WT
BMMC-reconstituted KitW-sh/W-sh mice restored at least par-
tially these variables at both time points. In contrast, most
variables did not differ significantly between KitW-sh/W-sh mice
and those that received Mcpt4/ BMMCs at either time point
(Figure 3B through 3F), supporting the hypothesis that
reduced AAA in Mcpt4/ mice resulted from the absence of
mMCP-4 from mast cells.
Chymase mMCP-4 Stimulates
Microvascularization and Vascular Cell Apoptosis
Microvascularization and cell death occur in human AAA.
Impaired angiogenesis and apoptosis in Mcpt4/ mice (Fig-
ure 2F and 2G) or in KitW-sh/W-sh mice that received Mcpt4/
BMMCs (Figure 3D and 3F) could result from reduced AAA
formation in these mice. To examine whether mMCP-4
participated directly in angiogenesis and vascular cell apo-
ptosis, we performed aortic ring microvessel outgrowth and
SMC apoptosis assays with the use of BMMCs from WT and
Mcpt4/ mice. Relative to WT BMMCs, those lacking
mMCP-4 showed greatly reduced activity in promoting aortic
ring microvessel outgrowth (Figure 4A). Earlier studies
suggested that mast cells contribute to microvessel growth via
VEGF23 but less so by releasing inflammatory cytokines
interleukin-6 (IL-6), interferon-, and tumor necrosis factor-.10
To test whether mMCP-4 deficiency affects mast cell VEGF
expression, we performed a VEGF enzyme-linked immu-
nosorbent assay on supernatants from degranulated mast cells
and lysates from WT and Mcpt4/ BMMCs and found no
significant differences (data not shown). We have previously
Table. Correlation Coefficient Between AAA Growth Rate and Different Confounders*
Variables MeanSEM (Range) or No. of Patients Standardized Coefficient ()† t P‡
Chymase, ng/mL 12.182.26 (8.76-23.40) 0.267 2.658 0.009
Initial AAA size, mm 33.694.14 (30.00-44.00) 0.198 1.957 0.054
Current smoking 62/103 0.121 1.187 0.238
Low-dose aspirin 46/103 0.058 0.565 0.574
ACE inhibitor 11/103 0.050 0.480 0.632
-Blockage 16/103 0.105 1.017 0.312
-Agonist 13/103 0.091 0.822 0.413
Steroid 10/103 0.299 2.656 0.009
Ankle-brachial index 1.000.22 (0.38-1.61) 0.048 0.474 0.636
Diastolic blood pressure, mm Hg 92.7013.27 (65.00-130.00) 0.048 0.487 0.627
Age, y 68.002.95 (64.30-73.70) 0.080 0.818 0.416
ACE indicates angiotensin-converting enzyme.
*All 103 patients are male.
†Multivariate linear regression analysis.
‡P0.05 was considered statistically significant.
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shown that WT BMMCs promote vascular SMC apoptosis.10
Mcpt4/ BMMCs conferred significant protection to SMCs
from pyrrolidinedithiocarbamate-induced apoptosis (Figure
4B), suggesting a direct role of mMCP-4 in both microvas-
cularization and apoptosis during the development of exper-
imental mouse AAA.
Deficiency of mMCP-4 Reduces Cysteine Protease
Cathepsin Expression in Mast Cells
Angiogenesis and apoptosis both require protease activities.
We have shown that the cysteine protease cathepsin S can
modulate microvessel growth.24,25 MMPs promote angiogen-
esis by triggering the release of VEGF.26 Cysteinyl cathepsins
also participate in apoptosis by cleaving the Bcl-2 family
member Bid followed by mitochondria cytochrome c re-
lease.27 Likewise, MMPs participate in cell death although
via different mechanisms.28 Considering reduced angiogene-
sis and apoptosis in Mcpt4/ mice (Figure 2C and 2F) or in
Mcpt4/ BMMC-reconstituted KitW-sh/W-sh mice (Figure 3D
and 3F), we hypothesized that absence of mMCP-4 affects
cathepsin and/or MMP expression. Mcpt4/ BMMCs had
significantly lower mRNA encoding all cathepsins tested,
including B, S, K, and L, compared with those in WT
BMMCs, as shown by RT-PCR. Although both MMP-2 and
-9 mRNAs were also higher in WT BMMCs than in Mcpt4/
BMMCs, their RNA levels remained low in WT BMMCs
(Figure 4C). MMPs in Mcpt4/ BMMCs were undetectable
by gelatin zymography (data not shown). To document
Figure 2. WT and Mcpt4/ mouse AAA lesion characterizations. Lesion aortic diameter changes (A), Mac-3 macrophage area percentage
(B), CD3 T cell number (C), SMC content in grades (D), elastin degradation in grades (E), apoptotic cells (F), and CD31 microvessel num-
bers (G) between WT and Mcpt4/ mice at 3 time points are shown. Representative photographs for panels B, C, F, and G are presented to
the right. Number of animals used for each experiment is indicated in each bar. Purified rat IgG was used as negative control (not shown). All
data are meanSEM. P0.05 was considered statistically significant (nonparametric Mann–Whitney test).
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further decreased cathepsin activities in Mcpt4/ BMMCs,
we performed cysteine protease active site labeling with
biotin-JPM. Mcpt4/ BMMCs showed reduced overall ca-
thepsin activities relative to WT BMMCs (Figure 4D).
Interestingly, we detected high levels of cathepsin L mRNA
but low levels of its active enzyme in WT BMMCs (Figure
4C and 4D), suggesting substantial regulation at the transla-
tion and/or activation levels. Assay of elastin degradation in
vitro supported this observation. An equal amount of cell
lysate from Mcpt4/ BMMCs degraded significantly less
elastin than those from WT BMMCs under conditions opti-
mized for cysteine protease cathepsins29 (Figure 4E), suggest-
ing that absence of mMCP-4 not only affects mast cell
cathepsin mRNAs but also their activities.
mMCP-4 Induces Aortic SMC
Cathepsin Activities
Mast cells induce vascular cell cathepsin expression via
inflammatory cytokines, and these cathepsins may in turn
participate in aortic wall remodeling.20 We tested whether
Mcpt4/ BMMCs demonstrate impaired ability to induce
vascular cell cathepsin expression. Culture of aortic SMCs
with BMMCs showed that WT BMMCs induced the activi-
ties of all major cysteinyl cathepsins to a much greater extent
than Mcpt4/ BMMCs. Mcpt4/ BMMC-treated SMCs had
reduced cathepsin B activity and negligible cathepsin S/K and
L/C activities compared with SMCs treated with WT BM-
MCs (Figure 4F). Thus, the absence of mMCP-4 in mast cells
not only altered mast cell cathepsin expression and activities
but also decreased the ability of mast cells to induce cathepsin
activity in vascular SMCs by an unknown mechanism.
Deficiency of mMCP-4 Reduces Aortic Wall
Cathepsin Activities
Reduced cathepsin activities in Mcpt4/ BMMCs and in
Mcpt4/ BMMC-treated SMCs suggest that reduced devel-
opment of AAA in Mcpt4/ mice resulted at least in part
from reduced cathepsin activities in the vessel wall. We
performed cathepsin active site labeling by incubating biotin-
JPM with aortic tissue extracts from WT and Mcpt4/ mice.
Consistent with our hypothesis, aortic tissues from Mcpt4/
mice contained much less cathepsin activity, especially cathe-
psins S/K, than those of WT mice (Figure 5A). In situ elastin
zymography yielded similar results. Under conditions opti-
mized for cathepsin activities (pH 5.5 with ethylenediami-
netetraacetic acid),29 frozen aortic sections from WT mice
Figure 3. KitW-sh/W-sh mice reconstitution and lesion characterization. Reconstitution of KitW-sh/W-sh mice with WT but not Mcpt4/
BMMCs restored partially the aortic expansion (A), lesion content of macrophages (B), CD3 T cell number (C), CD31 microvessel
number (D), level of aortic wall elastin degradation (E), and number of apoptotic cells (F) at both 14-day and 56-day time points. The
number of mice for each experimental group is indicated in the bar. All data are meanSEM. P0.05 was considered statistically sig-
nificant (nonparametric Mann–Whitney test).
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(Figure 5B) had greater activity in digesting fluorogenic
elastin than those from Mcpt4/ mice (Figure 5C).
Discussion
We have previously shown that mast cells play an important
role in mouse AAA formation.10 These cells produce cyto-
kines, chemokines, and proteases, all of which may partici-
pate in the pathogenesis of AAA.7–9 Like macrophages, mast
cells produce large quantities of cathepsins B, S, K, L, and
C.30 In contrast with macrophages, however, mast cells
express specialized proteases, including the serine protease
chymases. These proteases can activate MMPs and process
angiotensinogen to produce angiotensin II, mediators proven
critical in mouse AAA formation.14,31 Human AAA lesions
contain chymases and their substrates; whether these pro-
teases participate causally in the pathogenesis remains uncer-
tain. This study supports the hypothesis that mast cell
chymase participates directly in the pathogenesis of AAA
formation by assisting microvessel growth, vascular cell
apoptosis, and cysteinyl cathepsin expression and activation.
Yet these findings raise unanswered questions.
Preoperative glucocorticoid therapy has been associated
with benefit in isolated cases of inflammatory aneurysms.32
Such treatment in patients with AAA increases IL-10 (a
generally anti-inflammatory cytokine) and decreases IL-6 (a
proinflammatory cytokine) and levels of the inflammatory
marker C-reactive protein in serum.33,34 In contrast to these
beneficial effects, our data showed that patients who received
glucocorticoid therapy had a nearly doubled rate of AAA
growth (meanSEM, 3.540.49 versus 1.970.19 mm/y;
P0.01) compared with patients who did not receive the
therapy, although this treatment also significantly reduced the
Figure 4. Mast cell activities. A, Mouse aortic ring assay. VEGF was used as positive control. The number of rings for each experiment
is shown in the bar. Representative aortic rings are shown in the left panels. B, BMMC-mediated SMC apoptosis. Representative pho-
tographs are presented in the left panels. Green fluorescent cells are apoptotic SMCs. PDTC indicates pyrrolidinedithiocarbamate. C,
RT-PCR shows reduced cathepsins and MMP expression in Mcpt4/ BMMCs (meanSEM of 6 independent experiments). D, BMMC
cell lysate biotin-JPM labeling (representative of 3 independent experiments). E, Fluorogenic elastin degradation with BMMC cell
lysates. Data are meanSEM of 4 experiments. F, Biotin-JPM labeling of different live BMMC-treated mouse aortic SMC lysates.
GAPDH immunoblots were used for protein loading controls in D and F.
Figure 5. Reduced cathepsin activities in AAA lesions from Mcpt4/ mice. A, JPM labeling of mouse aortic tissue extracts. SDS-PAGE
Coomassie staining was used for protein loading control. Arrows indicate active cathepsins. B, WT mouse frozen AAA cross section in
situ elastase activity zymograph. C, Mcpt4/ mouse frozen AAA cross section in situ elastase activity zymograph. Lumen and percent-
age of fluorescence intensity are indicated. Images were obtained with the same magnification and shutter speed, and all data are from
the 14-day time point experiments.
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serum chymase levels (meanSEM, 10.770.31 versus
12.340.24 ng/mL; P0.04). Although this population in-
cluded only 10 patients receiving glucocorticoids, the data
indicate the potential of glucocorticoids as a strong con-
founder in the analysis of chymase activity and AAA pro-
gression and therefore the multivariate analysis included
these patients. The positive association between AAA growth
and use of glucocorticoids could be confounded by indica-
tion. For instance, patients often use glucocorticoids because
they have severe pulmonary obstructive disease, which inde-
pendently is associated with increased aortic expansion rate
and rupture risk.35 Alternatively, glucocorticoids can inhibit
vascular SMC proliferation36 and extracellular matrix protein
synthesis.37 Thus, in glucocorticoid-treated AAA, an unfavor-
able balance between extracellular matrix degradation versus
synthesis may prevail despite the steroid-induced muting of
aspects of inflammation, a hypothesis that requires further
investigation.
We found that mast cell chymase expression affected the
expression of other proteases. Reduced cysteinyl cathepsin
expression in Mcpt4/ BMMCs leads to the hypothesis that
the mechanism for the reduced AAA in Mcpt4/ mice might
result not only from the absence of mMCP-4 but also reduced
mast cell cathepsin expression. Although mMCP-4 can acti-
vate procollagenase, mMCP-4 itself is not a collagenase or an
elastase.38 Chymase mMCP-5 has elastinolytic activity, but
lack of mMCP-5 did not impair AAA formation (data not
shown). Therefore, neither mMCP-4 nor mMCP-5 alone
likely contributes to the massive aortic wall elastinolysis
during AAA formation. In contrast, cathepsins S, K, L, and C
are potent elastases and collagenases, and these secreted
cysteine proteases contributed to AAA formation15 (G. Shi,
DSc, unpublished data, 2009). Absence of mMCP-4 reduced
an array of elastinolytic and collagenolytic cathepsins in mast
cells, which may account in part for reduced elastinolysis in
Mcpt4/ mice (Figures 2E and 3E). Besides these cysteine
proteases, mMCP-4 deficiency also affected the expression of
cathepsin G, a serine protease present in human AAA capable
of elastin degradation and angiotensin II generation.39–41
BMMCs from Mcpt4/ mice had significantly lower levels
of cathepsin G transcripts than those in WT BMMCs after
normalizing to -actin transcripts (meanSEM, 0.0130.0005
versus 0.00060.0003; P0.00005), as shown by RT-PCR.
Thus, reduced mast cell cathepsin G expression may also
contribute to the observed attenuation in AAA formation in
Mcpt4/ mice.
Mast cell chymases promote angiogenesis42 and apopto-
sis.43 However, these in vitro studies employed purified
chymases in isolated cells. Direct involvement of chymase in
these processes in vivo remains unknown. This study showed
results similar to those of prior studies of angiogenesis and
apoptosis both in vitro (Figure 4A and 4B) and in vivo
(Figure 2F and 2G). Reduced cysteinyl cathepsin expression
and activities in Mcpt4/ BMMCs (Figure 4C through 4E)
and impaired ability of Mcpt4/ BMMCs to induce SMC
cathepsin expression raised the possibility that mast cell chy-
mases participate in arterial remodeling in part by regulating
cathepsin activities, a hypothesis that remains to be tested.
One important finding that we currently cannot explain is
the impact of mMCP-4 on cathepsin and MMP expression.
Our earlier observations from cathepsin S–deficient ECs
indicated that lack of cathepsin S did not change the expres-
sion or activities of other cathepsins, the cathepsin inhibitor
cystatin C, MMP, or tissue inhibitors of MMPs.24 Chymase
might participate in cathepsin activation, as it does in the case
of pro-MMPs,1 a hypothesis consistent with the observations
of decreased cathepsin activities in the absence of mMCP-4
in both interacting with biotin-conjugated JPM (Figure 4D)
and in degrading matrix elastin (Figure 4E). However, other
explanations may apply. Mast cells lacking mMCP-4 con-
tained greatly less cathepsin and MMP mRNA than did WT
mast cells, suggesting that mMCP-4 regulates transcription
and/or RNA-stability factors that control cathepsin expres-
sion. A protease that regulates the transcription of other
proteases has not been reported, but an indirect pathway is
possible. For instance, mast cell tryptase stimulates IL-8 and
IL-l expression by ECs.44 Chymase may act in a similar
manner. The resulting inflammatory cytokines can exhibit
autocrine and paracrine effects on protease expression.
Although not shown in this study, we found significantly
lower transmigration of BMMCs from Mcpt4/ mice
through collagen I–precoated filters compared with BMMCs
from WT mice, suggesting impaired mast cell recruitment or
accumulation to AAA lesions. However, the AAA of
Mcpt4/ and WT mice had similar MCP-1 levels and
CD117 mast cell numbers (data not shown). These data
suggest that mast cell transmigration in vitro requires pro-
tease activities but that other factors play more important
roles in mast cell accumulation during AAA development, a
hypothesis that merits further study. In conclusion, increased
mast cell chymase expression in human or mouse AAA
lesions directly promotes the pathological progression in part
by regulating pertinent protease expression and activities.
Inhibition of chymase activities limited experimental AAA
formation and may assist in attenuating the progression of
this irreversible human aortic disease.
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CLINICAL PERSPECTIVE
Mast cells, the primary players in allergic immune responses, have also been implicated in the pathogenesis of many
nonallergic human diseases, such as cancer, rheumatoid arthritis, and multiple sclerosis. We have recently shown that these
inflammatory cells play detrimental roles in the pathogenesis of both atherosclerosis and abdominal aortic aneurysm
(AAA). In mice, absence or inactivation of mast cells prevents the progression of these common vascular diseases,
providing the novel concept of controlling these diseases with the use of currently available generic mast cell stabilizers
in humans. Mechanistic analysis demonstrated that mast cells release proinflammatory cytokines to induce the expression
and secretion of atherosclerosis- and AAA-pertinent cysteine protease cathepsins from vascular smooth muscle cells and
endothelial cells. Such cysteinyl cathepsins have been suggested to participate directly in these vascular diseases mainly
through their elastase and collagenase activities. Like macrophages, mast cells have reservoirs of proteases. Besides
common cysteinyl cathepsins and matrix metalloproteinases, mast cells have the unique serine proteases tryptase and
chymase. In this study, we proved the direct involvement of chymase in aortic elastase perfusion–induced mouse AAA.
Mast cell chymases have been suggested to participate in vascular remodeling by activating matrix metalloproteinases and
generating angiotensin II, critical molecules in the pathogenesis of atherosclerosis and AAA. In addition to these known
pathological roles, we demonstrated in this study that mast cell chymases also control cysteinyl cathepsin expression and
activation, neovascularization, and aortic smooth muscle cell apoptosis. Reduced AAA formation from mice lacking mast
cell chymase and restoration of such reductions with reconstitution of mast cells from wild-type mice but not those of
chymase-deficient mice strongly support a direct participation of mast cell chymases in mouse AAA formation.
Observations of the AAA inhibitory effects of synthetic small-molecule orally active chymase inhibitor [2-(5-formylamino-
6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-(3,4-dioxo-1-phenyl-7-(2-pyridyloxy)-2-heptyl)acetamide; NK3201] in
several animal AAA models illustrate the possibility of controlling human AAA progression and associated complications
in the near future.
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SUPPLEMENTAL MATERIAL 
 
 
Supplemental Table 1.  Antibodies used in this study. 
____________________________________________________________________________________________________________________ 
 
Antibody name   Application   Supplier  Catalog Number Final Concentration 
____________________________________________________________________________________________________________________ 
 
mouse anti-human chymase  Immunohistochemistry  AbD Serotec          MCA1930                2 µg/ml 
 
mouse anti-human chymase  Immunoblot   AbD Serotec     MCA1930              2 µg/ml 
 
mouse anti-human chyamse  ELISA    AbD Serotec            MCA1930              0.2 µg/ml 
 
Biotin-mouse anti-human chymase ELISA    Millipore              MAB1254B          0.667 µg/ml 
 
Rat anti-mouse Mac-3   Immunohistochemistry            Pharmingen            553322                    0.555 µg/ml 
 
Rat anti-mouse a-actin   Immunohistochemistry            Sigma                   F3777                    5.6 µg/ml 
 
Rat anti-mouse CD3                            Immunohistochemistry            Pharmingen            555273               10 µg/ml 
 
Rat anti-mouse CD31   Immunohistochemistry            Pharmingen           553370                0.333 µg/ml 
 
Hamster anti-mouse MCP-1  Immunohistochemistry            Pharmingen         551217               20 µg/ml 
 
Rat anti-mouse c-Kit (CD117)  Immunohistochemistry            eBioscience          17-1171-83           4 µg/ml 
 
Rat IgG                                                Immunohistochemistry            Pharmingen              553985                5 µg/ml 
 
Mouse IgG                                           Immunohistochemistry         DAKO                       X0931                      0.5 µg/ml   
 
HRP-Avidin    Immunoblot   Sigma   A7419   0.36 µg/ml 
 
____________________________________________________________________________________________________________________ 
